Clinical Core

马萨诸塞州阿尔茨海默病研究中心：临床核心 马萨诸塞州阿尔茨海默病研究中心（MADRC）的临床核心与 MADRC作为一个整体：支持研究阿尔茨海默病的原因，机制和治疗 和阿尔茨海默病相关疾病（AD/ADRD），最终目标是治愈甚至预防。以促进 在这些领域的研究，我们正在改造我们的研究队列的男子和妇女从不同的种族和 种族背景，以实现更大数量和更大多样性的受损参与者，并追求 通用的深度临床、成像和分子表型分析。这将使队列作为我们的 中心的“实验室”，以了解疾病的异质性和加速治疗AD/ADRD。到 为了实现这些目标，我们有三个目标： 第一组（目标1-4）旨在调动资源，重点是发展和维持一个良好的 特征研究队列，以确保我们有足够数量的MCI和痴呆症， AD/ADRD。我们支持招募AD/ADRD中的受损个体，并将提交年度UDS 评估NACC和样本我们的参与者的遗传，流体和成像生物标志物，并获得 同意捐献大脑我们还维护着一个来自附属MGH记忆部门的患者数据库 诊所（记忆障碍，FTD和DLB），以参考更大的“研究准备”参与者池（研究 队列加临床患者）到广泛的地方和国家观察性研究和临床试验。 第二组目标（目标5-6）旨在制定新的战略，重点是实现普遍深入的 我们的研究队列的表型分析以及开发和验证用于早期诊断的新型临床仪器 用于临床环境和临床试验的检测。我们将使用我们的研究队列，深入的临床， 成像和分子表型，作为我们中心的“实验室”，以测试有关临床和 AD/ADRD的生物学差异和共性，并开发和验证生物标志物， 加快靶点发现和临床试验进程。我们将继续分享我们的数据和发现， 其他ADRC和更广泛的科学界进行验证和实施。 最后一组（目标7-8）旨在建设未来，重点是培养未来的临床医生- 科学家和促进痴呆症的预防工作和研究机会， 社区，特别是那些服务不足的少数民族。这些工作将在密切合作下进行 有REC和ORE Core。我们的目标是让所有利益相关者-患者，护理人员，临床医生和研究人员-参与进来 - 作为直接合作伙伴，加速治疗AD/ADRD。

Massachusetts Alzheimer’s Disease Research Center: Clinical Core The Clinical Core of the Massachusetts Alzheimer’s Disease Research Center (MADRC) parallels that of the MADRC as a whole: to support research into the causes, mechanisms and treatment of Alzheimer’s disease and Alzheimer-related disorders (AD/ADRD), with the eventual goal of cure and even prevention. To facilitate research in these areas, we are revamping our Research Cohort of men and women from diverse ethnic and racial backgrounds to achieve a larger number and greater diversity of impaired participants and pursue universal deep clinical, imaging, and molecular phenotyping. This will enable the Cohort to serve as our Center’s “laboratory” to understand disease heterogeneity and accelerate treatments for AD/ADRD. To accomplish these goals, we have three sets of Aims: The first group (Aims 1-4), intended to marshal resources, focuses on developing and maintaining a well- characterized Research Cohort to ensure that we have sufficient numbers of MCI and dementia across AD/ADRD. We bolster our recruiting of impaired individuals across AD/ADRD, and will submit annual UDS evaluations to NACC and sample our participants for genetic, fluid, and imaging biomarkers, plus obtain consent for brain donation. We also maintain a database of patients from the affiliated MGH Memory Division clinics (Memory Disorders, FTD and DLB) to refer a larger pool of “research ready” participants (Research Cohort plus Clinic Patients) to a wide range of local and national observational studies and clinical trials. The second group (Aims 5-6), intended to develop new strategies, focuses on achieving universal deep phenotyping of our Research Cohort and developing and validating novel clinical instruments for early detection for use in clinical settings and clinical trials. We will use our Research Cohort, with deep clinical, imaging and molecular phenotyping, as our Center’s “laboratory” to test hypotheses about clinical and biological differences and commonalities in AD/ADRD and to develop and validate biomarkers that may expedite target discovery and clinical trial process. We will continue to share our data and discoveries with other ADRCs and the broader scientific community for validation and implementation. The final group (Aims 7-8), intended to build the future, focuses on training future generations clinician- scientists and on promoting dementia prevention efforts and research opportunities to individuals in the community, particularly those from underserved minorities. These efforts will be done in close collaboration with REC and ORE Core. We aim to engage all stakeholders - patients, caregivers, clinicians and researchers - as direct partners to accelerate toward a cure for AD/ADRD.